1-20 of 43
J Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Max J Gordon, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Da Wei Huang, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Anna M Juanitez, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Colleen Ramsower, Lisa M. Rimsza, Allison P. Jacob, Heidi Simmons, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2024) 144 (Supplement 1): 750.
https://doi.org/10.1182/blood-2024-197956
Published: 2024
Journal Articles

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Arnold Bolomsky, Smriti Kanangat, Michele Ceribelli, Kristina Rinaldi, Lin Zhang, Elizabeth Hill, Jagan R. Muppidi, Craig J. Thomas, Ryan M. Young
Journal: Blood
Blood (2024) 144 (Supplement 1): 763.
https://doi.org/10.1182/blood-2024-208485
Published: 2024
Journal Articles

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Max J Gordon, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Da Wei Huang, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Anna M Juanitez, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Allison P. Jacob, Heidi Simmons, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2024) 144 (Supplement 1): 1722.
https://doi.org/10.1182/blood-2024-197987
Published: 2024
Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Margaret C. Lunn, George S. Laszlo, Sarah Eraiss, Mark T. Orr, Heidi K. Jessup, Henry Chan, Heather J. Thomas, Ann F. Cheung, Gregory P. Chang, Asya Grinberg, Eduardo Rodríguez-Arbolí, Sheryl Y. T. Lim, Allie R. Kehret, Jenny Huo, Frances M. Cole, Samuel C. Scharffenberger, Roland B. Walter
Journal: Blood
Blood (2023) 142 (Supplement 1): 1431.
https://doi.org/10.1182/blood-2023-185432
Published: 2023
Journal Articles

Molecular Mechanism of Action of Glucocorticoids in Lymphoma Therapy

Jaewoo Choi, Michele Ceribelli, James D Phelan, Björn Häupl, Da Wei Huang, George Wright, Tony Hsiao, Vivian M Morris, Francesco Ciccarese, Boya Wang, Sean R Corcoran, Sebastian Scheich, Xin Yu, Weihong Xu, Yandan Yang, Joyce Zhou, Grace Zhang, Jagan R. Muppidi, Giorgio Inghirami, Thomas Oellerich, Craig J. Thomas, Louis M. Staudt
Journal: Blood
Blood (2023) 142 (Supplement 1): 2986.
https://doi.org/10.1182/blood-2023-174325
Published: 2023
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023
Journal Articles

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Jan S. Rosenbaum, Amal S. Kolt, Scott B. Hoyt, Gregory M. Hayes, Brandi L. Soldo, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4152.
https://doi.org/10.1182/blood-2023-189899
Published: 2023
Journal Articles

Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies

Eric J Vick, Josh Bennett, Ashley E. Cochran, Kathleen Hueneman, Lyndsey C. Bolanos, Xiaohu Zhang, Crystal McKnight, Michele Ceribelli, Carleen Klumpp-Thomas, Kwangmin Choi, Kenneth Greis, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 45.
https://doi.org/10.1182/blood-2023-177797
Published: 2023
Journal Articles

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

Joshua Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery Sampson, Emma Uible, Eric Vick, Lyndsey C. Bolanos, Kathleen Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew Volk, Kenneth D. Greis, Jan Rosenbaum, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (11): 989–1007.
https://doi.org/10.1182/blood.2022018718
Published: 2023
Includes: Supplemental data
Journal Articles

Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8 + T-cell function and perturbed glycolysis

Sevgi Kostel Bal, Sarah Giuliani, Jana Block, Peter Repiscak, Christoph Hafemeister, Tala Shahin, Nurhan Kasap, Bernhard Ransmayr, Yirun Miao, Cheryl van de Wetering, Alexandra Frohne, Raul Jimenez Heredia, Michael Schuster, Samaneh Zoghi, Vanessa Hertlein, Marini Thian, Aleksandr Bykov, Royala Babayeva, Sevgi Bilgic Eltan, Elif Karakoc-Aydiner, Lisa E. Shaw, Iftekhar Chowdhury, Markku Varjosalo, Rafael J. Argüello, Matthias Farlik, Ahmet Ozen, Edgar Serfling, Loïc Dupré, Christoph Bock, Florian Halbritter, J. Thomas Hannich, Irinka Castanon, Michael J. Kraakman, Safa Baris, Kaan Boztug
Journal: Blood
Blood (2023) 142 (9): 827–845.
https://doi.org/10.1182/blood.2022018303
Published: 2023
Includes: Supplemental data
Journal Articles

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 2289–2291.
https://doi.org/10.1182/blood-2022-167887
Published: 2022
Journal Articles

IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Josh Bennett, Jennifer Yeung, Avery Sampson, Kathleen Hueneman, Mark Wunderlich, Kwangmin Choi, Andrew Volk, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 2240–2241.
https://doi.org/10.1182/blood-2022-167526
Published: 2022
Journal Articles

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

Jan S Rosenbaum, Scott B. Hoyt, Amal S. Kolt, Daniel A Luedtke, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 5949–5950.
https://doi.org/10.1182/blood-2022-167783
Published: 2022
Journal Articles

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6602–6603.
https://doi.org/10.1182/blood-2022-167950
Published: 2022
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Anna Marie Juanitez, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3537.
https://doi.org/10.1182/blood-2021-147032
Published: 2021
Journal Articles

Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity

Joonhee Park, Jay Daniels, Tim Wartewig, Kimberly G. Ringbloom, Maria Estela Martinez-Escala, Sara Choi, Jane J. Thomas, Peter G. Doukas, Jingyi Yang, Caroline Snowden, Calvin Law, Yujin Lee, Katie Lee, Yancong Zhang, Carly Conran, Kyle Tegtmeyer, Samuel H. Mo, David R. Pease, Balaji Jothishankar, Pui-Yan Kwok, Farah R. Abdulla, Barbara Pro, Abner Louissaint, Titus J. Boggon, Jeffrey Sosman, Joan Guitart, Deepak Rao, Jürgen Ruland, Jaehyuk Choi
Journal: Blood
Blood (2021) 138 (14): 1225–1236.
https://doi.org/10.1182/blood.2020009655
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141447
Published: 2020
Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Katelyn M. Melgar, PhD, LaQuita M Jones, DO, Mackenzie Walker, Lyndsey C Bolanos, BSc, Kathleen Hueneman, Mark Wunderlich, MS, Jiang-Kang Jiang, Kelli Wilson, Xiaohu Zhang, Patrick Sutter, Xin Xu, Kwangmin Choi, PhD, Gregory Tawa, Donald Lorimer, Jan Abendroth, Eric O'Brien, BSc, Scott Hoyt, Ellin Berman, MD, Christopher Famulare, MS, James C Mulloy, Ross L. Levine, MD, Jan S Rosenbaum, John P Perentesis, Craig J Thomas, PhD, Daniel T. Starczynowski, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3934.
https://doi.org/10.1182/blood-2019-124178
Published: 2019
Journal Articles

The Relevance of CD20 Targeting of Oncolytic Measles Virus in the Treatment of Adult Acute Lymphoblastic Leukemia

Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Sarah Aref, MSc, Aditi Dey, PhD, Rachel J Mitchell, MSc, Richard J Burt, MBBS, Naughton J Thomas, BSc, Dina Ahmed Said Aly Okasha, MBBS, MSc, Krisztina Zuborne Alapi, MSc, Adele K Fielding, MBBS,PhDFRCP,FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 3891.
https://doi.org/10.1182/blood.V130.Suppl_1.3891.3891
Published: 2017
Journal Articles

A Druggable TCF4 and BRD4 Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Michele Ceribelli, PhD, Priscilla N Kelly, Stefania Pittaluga, MD PhD, Craig J Thomas, PhD, Boris Reizis, PhD, Louis M. Staudt, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1513.
https://doi.org/10.1182/blood.V128.22.1513.1513
Published: 2016